Omega-3 and Adult ADHD: What the Evidence Shows

Omega-3 fatty acids (EPA and DHA) have a real, decades-long research base in ADHD — but almost all of it is in children and adolescents, and even there the picture is mixed. Two influential meta-analyses found small but statistically significant improvements in attention and hyperactivity ratings¹², while a more recent, more rigorous Cochrane review of 37 trials found little evidence that omega-3 outperforms placebo at all — and high-certainty evidence of no effect on the main parent-rated outcomes⁴. Where an effect does show up, it's consistently smaller than what stimulant or non-stimulant medication produces⁵. And research conducted specifically in adults with ADHD is thin — most of what exists on omega-3 and attention comes from pediatric trials that may or may not generalize to adult brains and adult-onset symptom patterns. This article lays out exactly what the studies found, what they didn't, and why Proco frames omega-3 as, at most, a modest adjunct alongside — never a substitute for — a clinical ADHD diagnosis, medication, or behavioral therapy.

What the pediatric research shows

The two most-cited meta-analyses on omega-3 and ADHD both come from children's trials, and both found a real but small effect.

Bloch and Qawasmi (2011) pooled 10 randomized placebo-controlled trials in 699 children and found omega-3 supplementation produced "a small but significant effect in improving ADHD symptoms," with EPA dose within supplements significantly correlated with efficacy. The authors were explicit that the effect was "modest compared with currently available pharmacotherapies for ADHD such as psychostimulants, atomoxetine, or α2 agonists" — their conclusion was that omega-3 might reasonably augment standard treatment, or serve as an option for families who decline medication, not replace it¹.

Hawkey and Nigg (2014) extended that analysis to 16 trials and 1,408 children and adolescents, finding a composite symptom effect size of g = 0.26 (95% CI 0.15–0.37) — a small effect by conventional standards. Their second analysis, of 9 studies in 586 participants, also found lower blood omega-3 levels in people with ADHD than controls (g=0.42). Notably, supplementation showed reliable effects on hyperactivity by both parent and teacher report, but on inattention by parent report only — a pattern worth holding onto, because parent ratings are the outcome the Cochrane review below scrutinises hardest.

Where the newer evidence disagrees

Two more recent, larger reviews complicate the picture further — in opposite directions.

A 2023 meta-analysis in The Journal of Clinical Psychiatry pooled 22 RCTs and 1,789 children and adolescents. The overall effect on core ADHD symptoms was not statistically significant (SMD −0.16, 95% CI −0.34 to 0.01, p = 0.07). But when the researchers isolated trials that ran 4 months or longer, the effect became significant (SMD −0.35, 95% CI −0.61 to −0.09, p = 0.007) — suggesting that if omega-3 helps at all, it may take sustained use to show up, and short trials may simply be underpowered to detect it³. Two nulls from the same analysis matter just as much, and are the reason the dose claim at the top of this page was wrong: neither a high EPA dose nor a high EPA:DHA ratio was found to improve ADHD symptoms. The authors also flagged moderate heterogeneity and small subgroup sample sizes as the study's main limitations.

Then, in the same year, an updated Cochrane review — generally considered the most rigorous form of evidence synthesis — pooled 37 trials and more than 2,374 children and adolescents and reached a more skeptical conclusion: "overall, there was little evidence that PUFA supplementation improved symptoms of ADHD in children and adolescents"⁴. Specifically, it found high-certainty evidence of no effect on parent-rated total ADHD symptoms (SMD −0.08, 95% CI −0.24 to 0.07; 16 studies, 1,166 participants), and high-certainty evidence of no difference on parent-rated inattention (SMD −0.01) or hyperactivity/impulsivity (SMD 0.09). In fairness to the other direction, it also found low-certainty evidence that children on PUFA may be more likely to improve than those on placebo (RR 1.95, 95% CI 1.47–2.60) — but that rested on 3 studies and 191 participants, against 16 studies and 1,166 participants for the high-certainty null. Side effects and dropout did not differ meaningfully from placebo.

Two meta-analyses found a small, real effect. The most rigorous review to date found high-certainty evidence of none on its main outcome. That's not a contradiction to paper over — it's the honest state of the evidence.

The adult evidence gap

Here's the part that matters most if you're an adult considering omega-3 for focus or attention: virtually none of the research above was conducted in adults. Bloch and Qawasmi's trials were in children. Hawkey and Nigg's were in children and adolescents. The 2023 Journal of Clinical Psychiatry meta-analysis and the 2023 Cochrane review were both restricted to children and adolescents. Even the NIH's National Center for Complementary and Integrative Health, summarizing the omega-3-and-ADHD literature for clinicians, discusses the evidence almost entirely in pediatric terms⁶.

That doesn't mean omega-3 doesn't do anything for adult attention — the underlying biology (DHA as a structural component of brain cell membranes, omega-3's role in neuronal signaling) doesn't stop applying at 18, and the general adult cognition literature is its own separate body of work. But it does mean the specific claim "omega-3 improves ADHD symptoms" rests almost entirely on data from a different population, at different doses, over different study designs, and adult-specific randomized trial data is thin to the point of being close to absent. We'd rather say that plainly than imply the pediatric evidence transfers cleanly. For the broader nutrition-and-attention picture beyond this one nutrient, see what the research actually says about nutrition and attention.

How omega-3 compares to ADHD medication

Scale matters here. The largest and most rigorous comparison available is a 2018 network meta-analysis in The Lancet Psychiatry, which pooled 133 double-blind randomized trials — 51 of them in adults — with 8,131 adults in the 12-week efficacy analysis⁵. In adults, on clinician-rated core ADHD symptoms, amphetamines produced an SMD of −0.79 (95% CI −0.99 to −0.58), methylphenidate −0.49 (−0.64 to −0.35), bupropion −0.46 (−0.85 to −0.07) and atomoxetine −0.45 (−0.58 to −0.32); modafinil was not better than placebo (0.16, −0.28 to 0.59). Set next to that, omega-3's best-case pediatric effect size (g = 0.26) is smaller than every medication that beat placebo in adults — roughly a third of the amphetamine estimate. This is why every meta-analysis in this space — including the ones favorable to omega-3 — frames it as a possible complement to treatment, not a comparable alternative. The same review found that those medications also carry real tolerability costs in adults, which is exactly the kind of trade-off a prescriber is there to weigh. Some of what looks like adult ADHD turns out to be something else, so what's actually different in an ADHD brain is worth reading before assuming which problem you're solving.

What this means if you have adult ADHD

ADHD in adults is a clinical diagnosis, made by a qualified professional, and the treatments with the strongest evidence behind them are medication and structured behavioral therapy. If you have — or suspect you have — adult ADHD, that's the evaluation and treatment path the evidence actually supports; nothing in this article is a substitute for it, and Proco doesn't market Omega-3 as one. Waiting times for that assessment are their own obstacle, which we've documented in what the UK wait actually looks like. If you're already on treatment and thinking about omega-3 as something additional, mention it to your prescriber first, particularly if you're on medication — read our breakdown of Cognitive Support and ADHD medication interactions for what to check before combining any supplement with a stimulant or non-stimulant prescription.

Proco's Omega-3 (180mg EPA + 120mg DHA per softgel) is dosed and disclosed for general cognitive support, not formulated or marketed as an ADHD treatment. Two softgels daily — the label's suggested use — deliver 360mg EPA and 240mg DHA, 600mg combined. We're not going to tell you that matches the ADHD trials: those trials used a wide range of doses, most of them higher, and the most recent analysis of the question found that raising the EPA dose or the EPA:DHA ratio didn't improve symptoms anyway. Our dosage guide sets out what different intakes correspond to. If focus and attention are the goal, it's also worth reading first whether what you're actually dealing with is ADHD or burnout — the two look similar day to day but call for very different responses.

Bottom line

Omega-3's evidence base for ADHD symptoms is real but modest, built almost entirely on children and adolescents, and genuinely mixed even within that population — two meta-analyses found a small significant benefit, the 2023 Cochrane review found high-certainty evidence of no effect on its main parent-rated outcomes. Adult-specific RCT data barely exists. Where an effect shows up it depends on trial length rather than dose, and it's consistently smaller than every ADHD medication that beats placebo in adults. That makes omega-3, at best, a modest adjunct worth discussing with a clinician alongside standard care — never a stand-in for diagnosis, medication, or therapy.

This article is for informational purposes only and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Speak with a healthcare provider before starting any new supplement, especially if you take medication or have an existing health condition.

References

1. Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry. 2011;50(10):991-1000. pubmed.ncbi.nlm.nih.gov/21961774
2. Hawkey E, Nigg JT. Omega-3 fatty acid and ADHD: blood level analysis and meta-analytic extension of supplementation trials. Clin Psychol Rev. 2014;34(6):496-505. pubmed.ncbi.nlm.nih.gov/25181335
3. Liu TH, Wu JY, Huang PY, et al. Omega-3 Polyunsaturated Fatty Acids for Core Symptoms of Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials. J Clin Psychiatry. 2023;84(5):22r14772. pubmed.ncbi.nlm.nih.gov/37656283
4. Gillies D, Leach MJ, Perez Algorta G. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2023;4:CD007986. pubmed.ncbi.nlm.nih.gov/37058600
5. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738. pubmed.ncbi.nlm.nih.gov/30097390
6. National Center for Complementary and Integrative Health. ADHD and Complementary Health Approaches: What the Science Says. nccih.nih.gov/health/providers/digest/adhd-science

Also worth reading: ADHD and Sleep: Why They So Often Overlap.

Want to know what's actually in what you take? Join the list — no spam, just it straight.